Head to Head Comparison: Poxel (PXXLF) vs. Novo Nordisk A/S (NVO)
Poxel (OTCMKTS:PXXLF) and Novo Nordisk A/S (NYSE:NVO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.
This is a summary of recent recommendations for Poxel and Novo Nordisk A/S, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Novo Nordisk A/S||1||5||6||0||2.42|
Risk and Volatility
Poxel has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Novo Nordisk A/S pays an annual dividend of $0.65 per share and has a dividend yield of 1.3%. Poxel does not pay a dividend. Novo Nordisk A/S pays out 27.8% of its earnings in the form of a dividend.
Insider and Institutional Ownership
6.8% of Novo Nordisk A/S shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Poxel and Novo Nordisk A/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Novo Nordisk A/S||34.94%||81.50%||38.73%|
Earnings & Valuation
This table compares Poxel and Novo Nordisk A/S’s gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Novo Nordisk A/S||$16.96 billion||6.99||$5.79 billion||$2.34||20.75|
Novo Nordisk A/S has higher revenue and earnings than Poxel.
Novo Nordisk A/S beats Poxel on 9 of the 10 factors compared between the two stocks.
Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis. Poxel SA has a licensing agreement with Enyo Pharmaceuticals for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of Hepatitis B. The company was founded in 2009 and is headquartered in Lyon, France.
About Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S has a collaboration agreement with Embark Biotech ApS for the discovery of novel treatments for obesity and its associated metabolic pathologies. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Receive News & Ratings for Poxel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poxel and related companies with MarketBeat.com's FREE daily email newsletter.